Improving health equity in pharmacogenomics communication
Health Equity and Risk Communication in Pharmacogenomics
This study is all about making sure everyone can get the right medications based on their genes, and it’s designed to help Dr. Loren Saulsberry learn how to bring this personalized approach to healthcare for all patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10911217 on NIH RePORTER |
What this research studies
This research focuses on enhancing the understanding and implementation of pharmacogenomics, which is the study of how genes affect a person's response to drugs. It aims to ensure that all patients, regardless of their background, receive equitable access to personalized medication based on their genetic makeup. The project involves training and mentorship for Dr. Loren Saulsberry, who will develop skills in implementation science and leadership to guide the integration of pharmacogenomics into clinical practice. By attending various educational workshops and seminars, she will gain the necessary expertise to lead future research in this field.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are interested in how their genetic information can influence their medication responses, particularly those from diverse backgrounds.
Not a fit: Patients who are not interested in pharmacogenomics or those who do not have access to genetic testing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective drug therapies for patients, improving treatment outcomes and reducing adverse drug reactions.
How similar studies have performed: Previous research has shown promising results in improving health outcomes through personalized medicine approaches, indicating that this area of study has potential for significant advancements.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Saulsberry, Loren — University of Chicago
- Study coordinator: Saulsberry, Loren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.